Amarin announces approval of BASF as additional supplier for Vascepa

Amarin announced the approval of the Supplemental New Drug Application, or sNDA, to the FDA for BASF as an additional Vascepa, or icosapent ethyl, active pharmaceutical ingredient supplier. The addition of BASF contributes to the planned expansion of the Vascepa manufacturing supply chain and is additional progress toward Amarin's goal to protect the commercial potential of Vascepa to beyond 2030 through a combination of patent protection, regulatory exclusivity, trade secrets and by taking advantage of manufacturing barriers to entry.